CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• CD47 is an immune checkpoint molecule mediating tumor immune escape via the 'don't eat me' signal.
• Elevated CD47 expression in lymphoma correlates with poor prognosis and varied subtype expression.
• CD47 blockade is a promising cancer immunotherapy target.

Purpose of the Study:

• To review the therapeutic potential of CD47 blockade in lymphoma.
• To analyze CD47 expression, mechanisms of action, and clinical challenges.
• To guide future clinical applications of CD47-targeting strategies.

Main Methods:

• Literature review integrating evidence on CD47 expression and mechanisms in lymphoma.
• Analysis of CD47 blockade's dual effects on immune cells and tumor signaling pathways.
• Assessment of current clinical challenges and emerging therapeutic strategies.

Main Results:

• CD47 blockade enhances macrophage phagocytosis via the CD47/SIRPα pathway, promoting tumor clearance.
• CD47 inhibition also disrupts thrombospondin-1 (TSP-1) and integrin signaling, yielding multifaceted anti-tumor effects.
• Clinical challenges include off-target toxicity and transient responses, necessitating novel approaches.

Conclusions:

• CD47 blockade demonstrates significant therapeutic potential in lymphoma by overcoming immune evasion.
• Combining CD47 inhibition with other therapies or gene editing may overcome resistance.
• Further research and clinical strategies are needed to optimize CD47-targeting therapies for lymphoma treatment.